GEN Exclusives

More »

GEN Exclusives

More »
Dec 30, 2011

2011 IPO Window for Biotechs Lets Through Fewer Companies

Just 13 firms went public compared to 16 in 2010, but discounts were smaller.

2011 IPO Window for Biotechs Lets Through Fewer Companies

Due to market volatility, more firms may go the M&A route rather than flocking to public markets. [© Lane Erickson - Fotolia.com]


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »